<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:33:19Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7726985" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7726985</identifier>
        <datestamp>2020-12-13</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7726985</article-id>
              <article-id pub-id-type="pmcid">PMC7726985</article-id>
              <article-id pub-id-type="pmc-uid">7726985</article-id>
              <article-id pub-id-type="pmid">32909497</article-id>
              <article-id pub-id-type="pmid">32909497</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.119.016239</article-id>
              <article-id pub-id-type="publisher-id">JAH35425</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Arrhythmia and Electrophysiology</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib id="jah35425-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Shantsila</surname>
                    <given-names>Eduard</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2429-6980</contrib-id>
                  <xref ref-type="aff" rid="jah35425-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35425-aff-0002">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>eduard.shantsila1@nhs.net</email>
                  </address>
                </contrib>
                <contrib id="jah35425-cr-0002" contrib-type="author">
                  <name>
                    <surname>Shahid</surname>
                    <given-names>Farhan</given-names>
                  </name>
                  <degrees>MRCP</degrees>
                  <xref ref-type="aff" rid="jah35425-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35425-cr-0003" contrib-type="author">
                  <name>
                    <surname>Sun</surname>
                    <given-names>Yongzhong</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah35425-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah35425-cr-0004" contrib-type="author">
                  <name>
                    <surname>Deeks</surname>
                    <given-names>Jonathan</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah35425-aff-0003">
                    <sup>3</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35425-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah35425-cr-0005" contrib-type="author">
                  <name>
                    <surname>Calvert</surname>
                    <given-names>Melanie</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah35425-aff-0004">
                    <sup>4</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35425-aff-0005">
                    <sup>5</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35425-aff-0006">
                    <sup>6</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35425-aff-0007">
                    <sup>7</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35425-aff-0008">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="jah35425-cr-0006" contrib-type="author">
                  <name>
                    <surname>Fisher</surname>
                    <given-names>James P.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7851-9222</contrib-id>
                  <xref ref-type="aff" rid="jah35425-aff-0009">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib id="jah35425-cr-0007" contrib-type="author">
                  <name>
                    <surname>Kirchhof</surname>
                    <given-names>Paulus</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="jah35425-aff-0002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35425-aff-0010">
                    <sup>10</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35425-aff-0011">
                    <sup>11</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35425-aff-0012">
                    <sup>12</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35425-aff-0013">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib id="jah35425-cr-0008" contrib-type="author">
                  <name>
                    <surname>Gill</surname>
                    <given-names>Paramjit S.</given-names>
                  </name>
                  <degrees>DM</degrees>
                  <xref ref-type="aff" rid="jah35425-aff-0014">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib id="jah35425-cr-0009" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Lip</surname>
                    <given-names>Gregory Y. H.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7566-1626</contrib-id>
                  <xref ref-type="aff" rid="jah35425-aff-0015">
                    <sup>15</sup>
                  </xref>
                  <xref ref-type="aff" rid="jah35425-aff-0016">
                    <sup>16</sup>
                  </xref>
                  <address>
                    <email>gregory.lip@liverpool.ac.uk</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jah35425-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">North Worcestershire VTS</named-content>
                <institution>St Helens and Knowsley Teaching Hospitals NHS Trust</institution>
                <city>Prescot</city>
                <named-content content-type="country-part">Merseyside</named-content>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Institute of Cardiovascular Sciences</named-content>
                <institution>University of Birmingham</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Birmingham Clinical Trials Unit</named-content>
                <named-content content-type="organisation-division">Institute of Applied Health Research</named-content>
                <institution>University of Birmingham</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">NIHR Birmingham Biomedical Research Centre</named-content>
                <institution>University of Birmingham</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Centre for Patient Reported Outcomes Research (CPROR)</named-content>
                <named-content content-type="organisation-division">Institute of Applied Health Research</named-content>
                <institution>University of Birmingham</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <institution>National Institute for Health Research (NIHR) Applied Research Centre West Midlands</institution>
                <institution>University of Birmingham</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <institution>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre</institution>
                <institution>University of Birmingham</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <named-content content-type="organisation-division">Birmingham Health Partners Centre for Regulatory Science and Innovation</named-content>
                <institution>University of Birmingham</institution>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0009">
                <label>
                  <sup>9</sup>
                </label>
                <named-content content-type="organisation-division">Department of Physiology</named-content>
                <named-content content-type="organisation-division">Faculty of Medical and Health Sciences</named-content>
                <institution>University of Auckland</institution>
                <country country="NZ">New Zealand</country>
              </aff>
              <aff id="jah35425-aff-0010">
                <label>
                  <sup>10</sup>
                </label>
                <institution>University Hospitals Birmingham NHS Foundation Trust</institution>
                <city>Birmingham</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0011">
                <label>
                  <sup>11</sup>
                </label>
                <institution>Sandwell and West Birmingham Hospitals NHS Trust</institution>
                <city>Birmingham</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0012">
                <label>
                  <sup>12</sup>
                </label>
                <institution>University Heart and Vascular Center</institution>
                <institution>UKE Hamburg</institution>
                <city>Hamburg</city>
                <country country="DE">Germany</country>
              </aff>
              <aff id="jah35425-aff-0013">
                <label>
                  <sup>13</sup>
                </label>
                <institution>German Center for Cardiovascular Research (DZHK), partner site Hamburg/Kiel/Lübeck</institution>
                <city>Hamburg</city>
                <country country="DE">Germany</country>
              </aff>
              <aff id="jah35425-aff-0014">
                <label>
                  <sup>14</sup>
                </label>
                <named-content content-type="organisation-division">Academic Unit of Primary Care</named-content>
                <named-content content-type="organisation-division">Warwick Medical School</named-content>
                <institution>University of Warwick</institution>
                <city>Coventry</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0015">
                <label>
                  <sup>15</sup>
                </label>
                <named-content content-type="organisation-division">Liverpool Centre for Cardiovascular Science</named-content>
                <institution>University of Liverpool and Liverpool Heart &amp; Chest Hospital</institution>
                <city>Liverpool</city>
                <country country="GB">United Kingdom</country>
              </aff>
              <aff id="jah35425-aff-0016">
                <label>
                  <sup>16</sup>
                </label>
                <named-content content-type="organisation-division">Aalborg Thrombosis Research Unit</named-content>
                <named-content content-type="organisation-division">Department of Clinical Medicine</named-content>
                <institution>Aalborg University</institution>
                <city>Aalborg</city>
                <country country="DK">Denmark</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Gregory Y. H. Lip, MD, Liverpool Centre for Cardiovascular Science, University of Liverpool, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, United Kingdom. E‐mail: <email>gregory.lip@liverpool.ac.uk</email><break/> or<break/>Eduard Shantsila, PhD, Institute of Population Health Sciences, University of Liverpool, Waterhouse Building, Block B, Brownlow Street, Liverpool, L69 3GL, United Kingdom. E‐mail: <email>eduard.shantsila1@nhs.net</email><break/></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>10</day>
                <month>9</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>15</day>
                <month>9</month>
                <year>2020</year>
              </pub-date>
              <volume>9</volume>
              <issue>18</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v9.18</issue-id>
              <elocation-id>e016239</elocation-id>
              <history>
                <date date-type="received">
                  <day>04</day>
                  <month>3</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>29</day>
                  <month>6</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright">Copyright &#x000a9; 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell<copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. </copyright-statement>
                <license license-type="creativeCommonsBy-nc">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-9-e016239.pdf"/>
              <abstract id="jah35425-abs-0001">
                <sec id="jah35425-sec-0001">
                  <title>Background</title>
                  <p>Patients with permanent atrial fibrillation have poor outcomes, exercise capacity, and quality of life even on optimal anticoagulation. Based on mechanistic and observational data, we tested whether the mineralocorticoid receptor antagonist spironolactone can improve exercise capacity, E/e' ratio, and quality of life in patients with permanent atrial fibrillation and preserved ejection fraction.</p>
                </sec>
                <sec id="jah35425-sec-0002">
                  <title>Methods and Results</title>
                  <p>The double‐masked, placebo‐controlled IMPRESS‐AF (Improved Exercise Tolerance in Heart Failure With Preserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation) trial (NCT02673463) randomized 250 stable patients with permanent atrial fibrillation and preserved left ventricular ejection fraction to spironolactone 25 mg daily or placebo. Patients were followed for 2 years. The primary efficacy outcome was peak oxygen consumption on cardiopulmonary exercise testing at 2 years. Secondary end points included 6‐minute walk distance, E/e' ratio, quality of life, and hospital admissions. Spironolactone therapy did not improve peak oxygen consumption at 2 years (14.0 mL/min per kg [SD, 5.4]) compared with placebo (14.5 [5.1], adjusted treatment effect, −0.28; 95% CI, −1.27 to 0.71]; <italic>P</italic>=0.58). The findings were consistent across all sensitivity analyses. There were no differences in the 6‐minute walking distance (adjusted treatment effect, −8.47 m; −31.9 to 14.9; <italic>P</italic>=0.48), E/e’ ratio (adjusted treatment effect, −0.68; −1.52 to 0.17, <italic>P</italic>=0.12), or quality of life (<italic>P</italic>=0.74 for EuroQol‐5 Dimensions, 5‐level version quality of life questionnaire and <italic>P</italic>=0.84 for Minnesota Living with Heart Failure). At least 1 hospitalization occurred in 15% of patients in the spironolactone group and 23% in the placebo group (<italic>P</italic>=0.15). Estimated glomerular filtration rate was reduced by 6 mL/min in the spironolactone group with &lt;1‐unit reduction in controls (<italic>P</italic>&lt;0.001). Systolic blood pressure was reduced by 7.2 mm Hg (95% CI, 2.2–12.3) in the spironolactone group versus placebo (<italic>P</italic>=0.005).</p>
                </sec>
                <sec id="jah35425-sec-0003">
                  <title>Conclusions</title>
                  <p>Spironolactone therapy does not improve exercise capacity, E/e' ratio, or quality of life in patients with chronic atrial fibrillation and preserved ejection fraction.</p>
                </sec>
                <sec id="jah35425-sec-0004">
                  <title>Registration</title>
                  <p>UTL: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrial.gov">https://www.clini​caltr​ial.gov</ext-link>; Unique identifier: NCT02673463. EudraCT number 2014‐003702‐33.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd id="jah35425-kwd-0001">atrial fibrillation</kwd>
                <kwd id="jah35425-kwd-0002">heart failure</kwd>
                <kwd id="jah35425-kwd-0003">preserved ejection fraction</kwd>
                <kwd id="jah35425-kwd-0004">randomized clinical trial</kwd>
                <kwd id="jah35425-kwd-0005">spironolactone</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Atrial Fibrillation</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institute for Health Research </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/501100000272</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>NIHR‐EME Programme</funding-source>
                  <award-id>12/10/19</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>NIHR Clinical Research Network West Midlands</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="4"/>
                <page-count count="10"/>
                <word-count count="7572"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>15 September 2020</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.1 mode:remove_FC converted:30.09.2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah35425-cit-1001">(<source xml:lang="en">J Am Heart Assoc</source>. <year>2020</year>;<volume>9</volume>:<elocation-id>e016239</elocation-id> DOI: <pub-id pub-id-type="doi">10.1161/JAHA.119.016239</pub-id>.)<pub-id pub-id-type="pmid">32909497</pub-id></mixed-citation>
              </p>
              <fn-group id="jah35425-ntgp-0001">
                <fn id="jah35425-note-1002">
                  <p>For Sources of Funding and Disclosures, see page 9.</p>
                </fn>
                <fn id="jah35425-note-1003">
                  <p>See Editorial by Ho</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah35425-body-0001">
            <def-list list-content="abbreviations" id="jah35425-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term>AF</term>
                <def>
                  <p>atrial fibrillation</p>
                </def>
              </def-item>
              <def-item>
                <term>BP</term>
                <def>
                  <p>blood pressure</p>
                </def>
              </def-item>
              <def-item>
                <term>IMPRESS‐AF</term>
                <def>
                  <p>Improved Exercise Tolerance in Heart Failure With Preserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation</p>
                </def>
              </def-item>
              <def-item>
                <term>MLWHF</term>
                <def>
                  <p>Minnesota Living with Heart Failure</p>
                </def>
              </def-item>
              <def-item>
                <term>NIHR</term>
                <def>
                  <p>National Institute for Health Research</p>
                </def>
              </def-item>
              <def-item>
                <term>VO<sub>2peak</sub></term>
                <def>
                  <p>peak oxygen consumption</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah35425-blkfxd-0001" orientation="portrait">
                <sec id="jah35425-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah35425-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah35425-list-0001">
                        <list-item>
                          <p>The study presents a randomized placebo controlled clinical trial of spironolactone versus placebo in patients with chronic atrial fibrillation and preserved ejection fraction.</p>
                        </list-item>
                        <list-item>
                          <p>Spironolactone therapy does not improve exercise capacity, endothelial function assessed as echocardiographic E/e' ratio, or quality of life in the tested population.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah35425-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah35425-list-0002">
                        <list-item>
                          <p>The trial does not support use of spironolactone therapy in patients with chronic atrial fibrillation and preserved ejection fraction.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="jah35425-sec-0009">
              <p>Patients with permanent atrial fibrillation (AF) have poor outcomes and reduced quality of life even when they receive appropriate stroke prevention therapy and have preserved left ventricular function.<xref rid="jah35425-bib-0001" ref-type="ref"><sup>1</sup></xref> The prognosis is worse when maintenance of the sinus rhythm cannot be achieved and the patients progress to persistent or permanent AF, even on optimal rate control.<xref rid="jah35425-bib-0002" ref-type="ref"><sup>2</sup></xref>
</p>
              <p>The mechanisms leading to reduced exercise capacity, related morbidity, and mortality in anticoagulated patients with permanent AF are likely related to disturbed diastolic ventricular function, myocardial fibrosis, and stiffening.<xref rid="jah35425-bib-0003" ref-type="ref"><sup>3</sup></xref>, <xref rid="jah35425-bib-0004" ref-type="ref"><sup>4</sup></xref> In fact, activators of fibroblast signaling such as fibroblast growth factor 23 are elevated in patients with chronic AF.<xref rid="jah35425-bib-0005" ref-type="ref"><sup>5</sup></xref> These changes can lead to ventricular filling abnormality, reducing cardiac output, and decreasing exercise capacity.<xref rid="jah35425-bib-0003" ref-type="ref"><sup>3</sup></xref>, <xref rid="jah35425-bib-0004" ref-type="ref"><sup>4</sup></xref> Aldosterone increases cardiac collagen deposition and left ventricular fibrosis.<xref rid="jah35425-bib-0006" ref-type="ref"><sup>6</sup></xref> This involves direct stimulation of cardiac fibroblasts by aldosterone to produce collagen with chronification of oxidative stress and inflammation in the heart.<xref rid="jah35425-bib-0007" ref-type="ref"><sup>7</sup></xref>, <xref rid="jah35425-bib-0008" ref-type="ref"><sup>8</sup></xref> Cardiac expression of mineralocorticoid receptors is increased in AF, thus augmenting the genomic effects of aldosterone.<xref rid="jah35425-bib-0009" ref-type="ref"><sup>9</sup></xref> According to a substudy of the RALES (Randomized Aldactone Evaluation Study) trial, the improved survival in patients with heart failure with impaired cardiac contractility treated by spironolactone was linked to its ability to reduce serum markers of ongoing fibrosis.<xref rid="jah35425-bib-0010" ref-type="ref"><sup>10</sup></xref> The recently published RACE‐3 (Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Persistent Atrial Fibrillation in Heart Failure Study), reporting a complex intervention that included spironolactone (&gt;75% difference in use between groups) suggested beneficial effects compared with usual care in patients with recent onset AF.<xref rid="jah35425-bib-0011" ref-type="ref"><sup>11</sup></xref>
</p>
              <p>The IMPRESS‐AF (Improved Exercise Tolerance in Heart Failure With Preserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation) trial therefore tested the effects of mineralocorticoid receptor inhibition with spironolactone in patients with permanent AF with preserved left ventricular ejection fraction compared with placebo on exercise capacity (primary outcome); and its effect on quality of life, diastolic function, all‐cause hospital admissions, and spontaneous cardioversion to sinus rhythm (secondary outcomes).</p>
            </sec>
            <sec sec-type="methods" id="jah35425-sec-0010">
              <title>Methods</title>
              <p>The data that support the findings of this study will be made available, provided the request is scientifically sound and from an appropriately qualified research group. All requests for data should be addressed to the corresponding authors.</p>
              <p>The IMPRESS‐AF trial is a double‐masked randomized placebo‐controlled multicenter enrollment single‐site management trial conducted in Birmingham, United Kingdom. The trial randomized 250 patients with permanent AF and preserved left ventricular function 1:1 to either spironolactone or placebo. Permanent AF was defined as at least 1‐year history of AF on all prescreening assessments with a previous decision to the accept rate control strategy and with further confirmation of AF on ECG at the screening. The previously published trial protocol was developed following the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement and the latest PRO‐specific guidance.<xref rid="jah35425-bib-0012" ref-type="ref"><sup>12</sup></xref>, <xref rid="jah35425-bib-0013" ref-type="ref"><sup>13</sup></xref> The study was approved by the National Research and Ethics Committee West Midlands—Coventry and Warwickshire (REC Reference 14/WM/1211). All patients provided signed informed consent. The study is registered at EudraCT number 2014‐003702‐33 and <ext-link ext-link-type="uri" xlink:href="http://Clinicaltrial.gov">Clini​caltr​ial.gov</ext-link> (NCT02673463). Because of the sensitive nature of the data collected for this study, requests to access the data set from qualified researchers trained in human subject confidentiality protocols may be sent to the University of Birmingham.</p>
              <p>Patients were recruited from primary care general/family practices and outpatient AF clinics in Sandwell and West Birmingham Hospitals Trust, Birmingham. The patients were ≥50 years with permanent AF, left ventricular ejection fraction ≥55%, and controlled blood pressure (BP).<xref rid="jah35425-bib-0014" ref-type="ref"><sup>14</sup></xref> An interpreter and translated materials were available if English was not their preferred language. The exclusion criteria (full list published previously<xref rid="jah35425-bib-0013" ref-type="ref"><sup>13</sup></xref>) included life expectancy of &lt;2 years, severe chronic obstructive pulmonary disease, severe mitral or aortal valve stenosis or regurgitation, rapidly progressing or severe renal impairment, potassium ≥5mmol/L, recent coronary artery bypass graft surgery (within 3 months), use of aldosterone antagonist or potassium sparing diuretic within 14 days. All patients received optimized treatment following established clinical guidelines on management of AF, heart failure, and hypertension.<xref rid="jah35425-bib-0015" ref-type="ref"><sup>15</sup></xref>
</p>
              <p>All patients were screened, investigated, and managed in the Research Clinic in the Institute of Cardiovascular Sciences, City Hospital, Birmingham. During the baseline visit, eligible patients underwent cardiopulmonary exercise testing using a cycling ergometer to measure peak oxygen consumption (VO<sub>2peak</sub>), 6‐minute walk test, and completed paper‐based quality of life questionnaires (validated Minnesota Living with Heart Failure<xref rid="jah35425-bib-0016" ref-type="ref"><sup>16</sup></xref> and EuroQol‐5 Dimensions, 5‐level version quality of life<xref rid="jah35425-bib-0017" ref-type="ref"><sup>17</sup></xref> questionnaires). A block randomization (block size of 4) was performed after the assessments using a secure web‐based randomization system. Patients were stratified by their baseline VO<sub>2peak</sub> of ≤16 and &gt;16 mL/min per kg. Patients, the trial team, care providers, outcome assessors, and data analysts were masked to the treatment allocation. Patients attended the research clinic every 3 months for follow‐up (Table <xref rid="jah35425-sup-0001" ref-type="supplementary-material">S1</xref>). The day‐to‐day management of the trial was coordinated by the Birmingham Clinical Trials Unit, registered by the National Institute for Health Research (NIHR) as a trials unit. A Trial Steering Committee was responsible for overseeing the progress of the trial. An independent Data Monitoring and Ethics Committee was responsible for the regular monitoring of trial data and adverse events.</p>
              <p>Patients randomized to spironolactone received 25 mg once daily for 2 years. In the case of an increase in potassium level to 5.1 to 5.5 mmol/L or non‐life‐threatening side effects (eg, gynecomastia) the dose was down‐titrated to 25 mg each second day with an attempt to re‐up‐titrate the dose if the reason for down‐titration has resolved. When potassium levels exceeded 5.5 mmol/L or if toxicity was suspected, the trial medication was stopped for the duration of the trial, but the patients were requested to attend the remaining follow‐up visits and their outcomes were included in the intention‐to‐treat analysis. Patient compliance to treatment was defined adequate when ≥80% of allocated capsules were taken.</p>
              <p>The primary hypothesis was assessed by the difference between trial groups in VO<sub>2peak</sub> on cardiopulmonary exercise testing<xref rid="jah35425-bib-0018" ref-type="ref"><sup>18</sup></xref>, <xref rid="jah35425-bib-0019" ref-type="ref"><sup>19</sup></xref> at 2 years, adjusted for the baseline values. The Secondary efficacy end points were 6‐minute walk test distance, quality of life using Minnesota Living with Heart Failure, and EuroQol‐5 Dimensions questionnaires, diastolic function assessed by E/E’ ratio<xref rid="jah35425-bib-0020" ref-type="ref"><sup>20</sup></xref>, <xref rid="jah35425-bib-0021" ref-type="ref"><sup>21</sup></xref> on echocardiography, rates of all‐cause hospital admissions and spontaneous return to sinus rhythm on ECG. Prespecified safety outcomes were occurrence of breast pain or swelling, allergic reaction, raised serum creatinine (&gt;220 μmol/L), low estimated glomerular filtration (&lt;30 mL/min per 1.73m<sup>2</sup>), and hyperkalemia (≥5.1 and ≥6.0 mmol/L).</p>
              <sec id="jah35425-sec-0011">
                <title>Statistical Analysis</title>
                <p>All primary analyses followed modified intention to treat principles including all patients reporting outcomes regardless of their compliance with the medication. For the primary outcome patients who died before the 2‐year follow‐up assessment were additionally included with VO<sub>2peak</sub> scores at 2 years imputed as 0 regardless of cause; 3 sensitivity analyses were undertaken for the primary outcome (further details are available in Data <xref rid="jah35425-sup-0001" ref-type="supplementary-material">S1</xref>). Further analyses included additional adjustments for age, sex, and body mass index at baseline. Pre‐defined subgroup analyses compared the difference in primary outcome VO<sub>2peak</sub> between spironolactone and placebo according to VO<sub>2peak</sub>; age, sex, body mass index, systolic and diastolic BP. Details of the statistical methodology for the secondary outcome measures are available in Data <xref rid="jah35425-sup-0001" ref-type="supplementary-material">S1</xref>. Analyses of the study outcomes were defined in a statistical analysis plan, signed off before unmasking. Results are presented in accordance with CONSORT and CONSORT PRO.<xref rid="jah35425-bib-0022" ref-type="ref"><sup>22</sup></xref> STATA version 12 software was used for all analyses.</p>
              </sec>
              <sec id="jah35425-sec-0012">
                <title>Sample Size</title>
                <p>Sample size was determined to be able to show a clinically important difference in the primary outcome of VO<sub>2peak</sub>. Published values of VO<sub>2peak</sub> in subjects with heart failure give baseline values (mean 16 [SD 5] mL/min per kg).<xref rid="jah35425-bib-0023" ref-type="ref"><sup>23</sup></xref> A difference of 2 mL/min per kg was judged to be clinically relevant. A sample size of 100 patients in each arm would give the power of at least 80% to detect differences in primary and secondary end points of a magnitude consistent with published results from similar studies. We increased the sample size to 125 per arm for provision for a 20% dropout rate. Statistical power would be higher with the benefits of adjusting for baseline values.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah35425-sec-0013">
              <title>Results</title>
              <p>A total of 250 patients were randomized to spironolactone or placebo (125 per group). Patients were elderly (mean age, 72.3 [SD, 7.4] years, further details in Table <xref rid="jah35425-tbl-0001" ref-type="table">1</xref>). Random groups were well balanced (Table <xref rid="jah35425-tbl-0001" ref-type="table">1</xref>). The final study visit was attended by 101 (81%) patients randomized to spironolactone and 106 (85%) randomized to placebo (Figure <xref rid="jah35425-fig-0001" ref-type="fig">1</xref>). Spironolactone had the expected effect on BP and kidney function. Systolic BP was reduced by 7.2 mm Hg (95% CI, 2.2–12.3) in the spironolactone group, almost no change in the placebo group (Table <xref rid="jah35425-sup-0001" ref-type="supplementary-material">S2</xref>). There was no significant treatment effect for diastolic BP. Spironolactone increased creatinine (mmol/L) by 6.9 (95% CI, 3.4–10.5) and lowered estimated glomerular filtration rate (mL/min per 1.73) by 6.0 (95% CI, −9.3 to −2.8) at 2 years.</p>
              <table-wrap id="jah35425-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                <label>Table 1</label>
                <caption>
                  <p>Baseline Characteristics</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <thead valign="top">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="top" rowspan="1" colspan="1"/>
                      <th align="center" valign="top" rowspan="1" colspan="1">
                        <p>Spironolactone</p>
                        <p>(n=125)</p>
                      </th>
                      <th align="center" valign="top" rowspan="1" colspan="1">
                        <p>Placebo</p>
                        <p>(n=125)</p>
                      </th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" colspan="3" rowspan="1">Demographic characteristics</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age, y</td>
                      <td align="char" char="(" rowspan="1" colspan="1">73 (68–77)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">72 (67–78)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="3" rowspan="1">Sex</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Women</td>
                      <td align="char" char="(" rowspan="1" colspan="1">28 (22%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">31 (25%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Men</td>
                      <td align="char" char="(" rowspan="1" colspan="1">97 (78%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">94 (75%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="3" rowspan="1">Ethnicity</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">White</td>
                      <td align="char" char="(" rowspan="1" colspan="1">118 (94%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">118 (94%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Black</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (2%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (2%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Asian</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (2%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">2 (2%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Ethnicity other than White, Black, or Asian or mixed ethnicity of White, Black and/or Asian background</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">2 (2%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="3" rowspan="1">Smoker</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Current smoker</td>
                      <td align="char" char="(" rowspan="1" colspan="1">6 (5%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (6%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Ex‐smoker</td>
                      <td align="char" char="(" rowspan="1" colspan="1">66 (53%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">68 (54%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Never smoked</td>
                      <td align="char" char="(" rowspan="1" colspan="1">53 (42%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">49 (39%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Alcohol use, units/wk</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (0–12)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">6 (0–14)</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="3" rowspan="1">Characteristics of the study outcomes</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">VO<sub>2peak</sub>, mL/kg per min</td>
                      <td align="char" char="(" rowspan="1" colspan="1">14 (11–18)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">14 (11–18)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">VO<sub>2peak</sub> of ≤16 mL/kg per min</td>
                      <td align="char" char="(" rowspan="1" colspan="1">77 (62%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">78 (62%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">6‐min walk test, m</td>
                      <td align="char" char="(" rowspan="1" colspan="1">266 (196–316)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">271 (200–330)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">E/E’ ratio</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9.8 (8.0–12.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9.7 (7.5–13.0)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="3" rowspan="1">E/E’ ratio categories</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">&lt;10</td>
                      <td align="char" char="(" rowspan="1" colspan="1">66 (52.8%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">64 (51.2%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">≥10 to &lt;14</td>
                      <td align="char" char="(" rowspan="1" colspan="1">41 (32.8%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">39 (31.2%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">≥14</td>
                      <td align="char" char="(" rowspan="1" colspan="1">18 (14.4%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">22 (17.6%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="3" rowspan="1">EQ‐5D‐5L</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Score</td>
                      <td align="char" char="(" rowspan="1" colspan="1">0.84 (0.74–0.94)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">0.88 (0.74–0.94)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Missing data</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (3%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">5 (4%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="3" rowspan="1">MLWHF score</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Score</td>
                      <td align="char" char="(" rowspan="1" colspan="1">7.0 (6.3–35.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">14.0 (5.8–30.0)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Missing data</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (6%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (3%)</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="3" rowspan="1">Clinical characteristics</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Left ventricular ejection fraction (%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">58 (57–62)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">58 (56–63)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Brain natriuretic peptide, pg/mL</td>
                      <td align="char" char="(" rowspan="1" colspan="1">122 (73–230)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">136 (82–241)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Brain natriuretic peptide &gt;130 ng/L</td>
                      <td align="char" char="(" rowspan="1" colspan="1">56 (44.8%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">66 (52.8%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Body mass index, kg/m<sup>2</sup>
</td>
                      <td align="char" char="(" rowspan="1" colspan="1">29 (26–33)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">30 (26–34)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic blood pressure, mm Hg</td>
                      <td align="char" char="(" rowspan="1" colspan="1">130 (117–140)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">129 (118–142)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic blood pressure, mm Hg</td>
                      <td align="char" char="(" rowspan="1" colspan="1">75 (67–83)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">74 (68–82)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Resting heart rate, bpm</td>
                      <td align="char" char="(" rowspan="1" colspan="1">85 (74–99)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">83 (74–97)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus</td>
                      <td align="char" char="(" rowspan="1" colspan="1">24 (19%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">21 (17%)</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="3" rowspan="1">Medications</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Non‐vitamin K oral anticoagulants</td>
                      <td align="char" char="(" rowspan="1" colspan="1">60 (48%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">57 (46%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Vitamin K antagonists</td>
                      <td align="char" char="(" rowspan="1" colspan="1">47 (38%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">47 (38%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td>
                      <td align="char" char="(" rowspan="1" colspan="1">10 (8%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9 (7%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Clopidogrel</td>
                      <td align="char" char="(" rowspan="1" colspan="1">6 (5%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (3%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Loop diuretic</td>
                      <td align="char" char="(" rowspan="1" colspan="1">25 (20%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">24 (19%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Thiazide diuretic</td>
                      <td align="char" char="(" rowspan="1" colspan="1">14 (11%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">20 (16%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Angiotensin‐converting enzyme inhibitor or angiotensin receptor blocker</td>
                      <td align="char" char="(" rowspan="1" colspan="1">67 (54%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">80 (64%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Calcium channel blocker</td>
                      <td align="char" char="(" rowspan="1" colspan="1">43 (34%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">37 (30%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Beta blocker</td>
                      <td align="char" char="(" rowspan="1" colspan="1">66 (53%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">70 (56%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Digoxin</td>
                      <td align="char" char="(" rowspan="1" colspan="1">26 (21%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">23 (18%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Amiodarone</td>
                      <td align="char" char="(" rowspan="1" colspan="1">0 (0%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Statin</td>
                      <td align="char" char="(" rowspan="1" colspan="1">88 (70%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">69 (55%)</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Inhalers of asthma or COPD</td>
                      <td align="char" char="(" rowspan="1" colspan="1">20 (16%)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">17 (14%)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah35425-ntgp-0002">
                  <fn id="jah35425-note-0004">
                    <p>Continuous data presented as median (interquartile range). To score Minnesota Living with Heart Failure questionnaire, it was allowed that at most 20% of 21 responses were missing which was equivalent to 4 data items. If there were ≤4 data items missing then we used mean substitution to impute the missing responses and then scored the questionnaire by summating the responses to all 21 questions; otherwise, the person's score was left missing. EQ‐5D‐5L indicates EuroQol‐5 Dimensions, 5‐level version quality of life questionnaire; COPD, chronic obstructive pulmonary disease; MLWHF indicates Minnesota Living with Heart Failure; and VO<sub>2peak</sub>, peak oxygen consumption.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig fig-type="Figure" xml:lang="en" id="jah35425-fig-0001" orientation="portrait" position="float">
                <label>Figure 1</label>
                <caption>
                  <title>CONSORT flow diagram.</title>
                  <p>EQ‐5D indicates EuroQol‐5 Dimensions, 5‐level version quality of life questionnaire; FU, follow up; IMP, investigational medicinal product; and MLWHF, Minnesota Living with Heart Failure.</p>
                </caption>
                <graphic id="nlm-graphic-1" xlink:href="JAH3-9-e016239-g001"/>
              </fig>
              <p>Data on the primary outcome, VO<sub>2peak</sub> at the end of the trial were available for 106 patients in placebo group and 103 patients in spironolactone group (Table <xref rid="jah35425-tbl-0002" ref-type="table">2</xref>), which included 3 deaths in placebo group and 5 deaths in spironolactone group. In both groups, 3 patients were not able to perform cardiopulmonary exercise testing because of frailty. In the primary intention to treat analysis, VO<sub>2peak</sub> (mL/min per kg) changed from mean 14.5 (SD 4.6) to mean 14.0 (SD 5.4) in the spironolactone group and from mean 14.6 (SD, 5.1) to mean 14.5 (SD, 5.1) in placebo group. The treatment effect showed no difference between the groups (differences in mean −0.28, 95% CI, −1.27 to 0.71; <italic>P</italic>=0.58). The findings were consistent across the performed sensitivity analyses (Table <xref rid="jah35425-tbl-0002" ref-type="table">2</xref>, Table <xref rid="jah35425-sup-0001" ref-type="supplementary-material">S3</xref>).</p>
              <table-wrap id="jah35425-tbl-0002" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                <label>Table 2</label>
                <caption>
                  <p>Study Outcomes</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <thead valign="top">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="2" valign="top" colspan="1"/>
                      <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Spironolactone</th>
                      <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo</th>
                      <th align="center" style="border-bottom:solid 1px #000000" valign="top" rowspan="1" colspan="1">Treatment Effect<xref ref-type="fn" rid="jah35425-note-0006">*</xref>
</th>
                      <th align="center" rowspan="2" valign="top" colspan="1"><italic>P</italic> Value<xref ref-type="fn" rid="jah35425-note-0006">*</xref>
</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="center" valign="top" rowspan="1" colspan="1">Mean (SD)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">n</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Mean (SD)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">n</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">(95% CI)<xref ref-type="fn" rid="jah35425-note-0007">†</xref>
</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" colspan="7" rowspan="1">Primary outcome<xref ref-type="fn" rid="jah35425-note-0007">†</xref>
</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">VO<sub>2peak</sub>, mL/kg per min</td>
                      <td align="left" rowspan="1" colspan="1">14.0 (5.4)</td>
                      <td align="char" char="." rowspan="1" colspan="1">103</td>
                      <td align="left" rowspan="1" colspan="1">14.5 (5.1)</td>
                      <td align="char" char="." rowspan="1" colspan="1">106</td>
                      <td align="left" rowspan="1" colspan="1">−0.28 (−1.27 to 0.71)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.58</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="7" rowspan="1">Primary outcome sensitivity analysis</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Per protocol analysis:<xref ref-type="fn" rid="jah35425-note-0008">‡</xref> VO<sub>2peak</sub>, mL/kg per min</td>
                      <td align="left" rowspan="1" colspan="1">14.8 (4.3)</td>
                      <td align="char" char="." rowspan="1" colspan="1">57</td>
                      <td align="left" rowspan="1" colspan="1">14.9 (4.9)</td>
                      <td align="char" char="." rowspan="1" colspan="1">77</td>
                      <td align="left" rowspan="1" colspan="1">0.21 (−0.78 to 1.21)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.67</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Complete case analysis: VO<sub>2peak</sub>, mL/kg per min</td>
                      <td align="left" rowspan="1" colspan="1">14.8 (4.5)</td>
                      <td align="char" char="." rowspan="1" colspan="1">98</td>
                      <td align="left" rowspan="1" colspan="1">14.9 (4.6)</td>
                      <td align="char" char="." rowspan="1" colspan="1">103</td>
                      <td align="left" rowspan="1" colspan="1">−0.09 (−0.86 to 0.68)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.81</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Multiple imputation method:<xref ref-type="fn" rid="jah35425-note-0009">§</xref> VO<sub>2peak</sub>, mL/kg per min</td>
                      <td align="left" rowspan="1" colspan="1">13.4 (6.0)<xref ref-type="fn" rid="jah35425-note-0010">‖</xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">125</td>
                      <td align="left" rowspan="1" colspan="1">14.0 (5.5)<xref ref-type="fn" rid="jah35425-note-0010"> ‖</xref>
</td>
                      <td align="char" char="." rowspan="1" colspan="1">125</td>
                      <td align="left" rowspan="1" colspan="1">−0.53 (−1.57 to 0.51)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.32</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Adjusted for stratification variable and BNP level: VO<sub>2peak</sub>, mL/kg per min</td>
                      <td align="left" rowspan="1" colspan="1">14.0 (5.4)</td>
                      <td align="char" char="." rowspan="1" colspan="1">103</td>
                      <td align="left" rowspan="1" colspan="1">14.5 (5.1)</td>
                      <td align="char" char="." rowspan="1" colspan="1">106</td>
                      <td align="left" rowspan="1" colspan="1">−0.32 (−1.31 to 0.68)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.53</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Analysis removing patients who died and could not perform CPET (assigned to a peak VO<sub>2</sub> of 0) at follow‐up: VO<sub>2peak</sub>, mL/kg per min<xref ref-type="fn" rid="jah35425-note-0011">¶</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">14.8 (4.6)</td>
                      <td align="char" char="." rowspan="1" colspan="1">98</td>
                      <td align="left" rowspan="1" colspan="1">14.9 (4.6)</td>
                      <td align="char" char="." rowspan="1" colspan="1">103</td>
                      <td align="left" rowspan="1" colspan="1">−0.09 (−0.86, 0.68)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.81</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="7" rowspan="1">Secondary outcomes</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">6‐min walk test distance, m<xref ref-type="fn" rid="jah35425-note-0007">†</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">313 (108)</td>
                      <td align="char" char="." rowspan="1" colspan="1">105</td>
                      <td align="left" rowspan="1" colspan="1">330 (112)</td>
                      <td align="char" char="." rowspan="1" colspan="1">107</td>
                      <td align="left" rowspan="1" colspan="1">−8.47 (−31.9 to 14.9)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.48</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">E/Eʹ ratio</td>
                      <td align="left" rowspan="1" colspan="1">9.00 (3.05)</td>
                      <td align="char" char="." rowspan="1" colspan="1">101</td>
                      <td align="left" rowspan="1" colspan="1">9.72 (3.57)</td>
                      <td align="char" char="." rowspan="1" colspan="1">106</td>
                      <td align="left" rowspan="1" colspan="1">−0.68 (−1.52 to 0.17)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.12</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Brain natriuretic peptide, pg/mL</td>
                      <td align="left" rowspan="1" colspan="1">179 (171)</td>
                      <td align="char" char="." rowspan="1" colspan="1">101</td>
                      <td align="left" rowspan="1" colspan="1">186 (110)</td>
                      <td align="char" char="." rowspan="1" colspan="1">105</td>
                      <td align="left" rowspan="1" colspan="1">4.95 (−28.3 to 38.2)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.77</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">EQ‐5D‐5L score<xref ref-type="fn" rid="jah35425-note-0007">†</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">0.81 (0.26)</td>
                      <td align="char" char="." rowspan="1" colspan="1">98</td>
                      <td align="left" rowspan="1" colspan="1">0.84 (0.21)</td>
                      <td align="char" char="." rowspan="1" colspan="1">104</td>
                      <td align="left" rowspan="1" colspan="1">−0.008 (−0.06 to 0.04)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.74</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">MLWHF score<xref ref-type="fn" rid="jah35425-note-0012">#</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">17.4 (22.7)</td>
                      <td align="char" char="." rowspan="1" colspan="1">96</td>
                      <td align="left" rowspan="1" colspan="1">15.3 (20.4)</td>
                      <td align="char" char="." rowspan="1" colspan="1">104</td>
                      <td align="left" rowspan="1" colspan="1">0.49 (−4.32 to 5.29)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.84</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah35425-ntgp-0003">
                  <fn id="jah35425-note-0005">
                    <p>BNP, brain natriuretic peptide; CPET indicates cardiopulmonary exercise testing; EQ‐5D‐5L, EuroQol‐5 Dimensions, 5‐level version quality of life questionnaire; MLWHF, Minnesota Living with Heart Failure; VO<sub>2peak,</sub> peak oxygen consumption.</p>
                  </fn>
                  <fn id="jah35425-note-0006">
                    <label>*</label>
                    <p>The mean differences between the spironolactone group and placebo group, 95% CIs, and the corresponding <italic>P</italic> values were estimated from linear regression models adjusting for the baseline continuous peak oxygen consumption score. In the sensitivity analyses additional adjustments were made for age, sex, and body mass index.</p>
                  </fn>
                  <fn id="jah35425-note-0007">
                    <label>†</label>
                    <p>A value of 0 was assigned to peak oxygen consumption, 6‐minute walk test, and EuroQol‐5 Dimensions, 5‐level version quality of life questionnaire scores for those who died.</p>
                  </fn>
                  <fn id="jah35425-note-0008">
                    <label>‡</label>
                    <p>Per‐protocol population was defined as ≥80% of capsules taken.</p>
                  </fn>
                  <fn id="jah35425-note-0009">
                    <label>§</label>
                    <p>Predictive Mean Matching imputation method was used to generate 20 imputed data sets. Data for participants in spironolactone group and placebo group were imputed separately. peak oxygen consumption<sub>,</sub> age, body mass index, systolic/diastolic blood pressure, 6‐minute walk test, brain natriuretic peptide level, E/E’ ratio, EuroQol‐5 Dimensions, 5‐level version quality of life, Minnesota Living with Heart Failure scores at baseline and sex were included in the imputation model.</p>
                  </fn>
                  <fn id="jah35425-note-0010">
                    <label>‖</label>
                    <p>SD estimates were obtained by multiplying the standard error by the square root of 125.</p>
                  </fn>
                  <fn id="jah35425-note-0011">
                    <label>¶</label>
                    <p>Total of 8 exclusions; 5 from spironolactone, and 3 from placebo.</p>
                  </fn>
                  <fn id="jah35425-note-0012">
                    <label>#</label>
                    <p>For Minnesota Living with Heart Failure questionnaire, score ranges from 0 to 105 with a higher score reflecting poorer quality of life; the highest value across the whole participants was assigned to those who died. All patients choose to use the English version of the questionnaires with only 1 proxy completion case recorded (placebo group is the reference group).</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>The subgroup analyses showed no significant interaction of treatment with baseline VO<sub>2peak</sub> values (mL/min per kg, ≤16 versus &gt;16, <italic>P</italic>=0.54), body mass index (kg/m<sup>2</sup>, &lt;25 versus 25–30 versus ≥30, <italic>P</italic>=0.13), sex (<italic>P</italic>=0.91), median BP (<italic>P</italic>=0.36 for systolic BP and <italic>P</italic>=0.93 for diastolic BP), and E/E’ ratio (&lt;10 versus 10–14 versus ≥14, <italic>P</italic>=0.73) (Table <xref rid="jah35425-tbl-0003" ref-type="table">3</xref>). There was a significant interaction between treatment and age: higher VO<sub>2peak</sub> values were observed in older patients randomized to spironolactone, but in younger patients in placebo group (<italic>P</italic>=0.03 for interaction). The magnitude of the differences was small, with the point estimates for the treatment effect in each subgroup being smaller than the pre‐stated clinically important treatment effect.</p>
              <table-wrap id="jah35425-tbl-0003" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                <label>Table 3</label>
                <caption>
                  <p>Subgroup Analysis of the Primary Outcome</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <thead valign="top">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" rowspan="2" valign="top" colspan="1">Analyses</th>
                      <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Spironolactone</th>
                      <th align="center" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo</th>
                      <th align="center" rowspan="2" valign="top" colspan="1">Treatment Effect (95% CI)<xref ref-type="fn" rid="jah35425-note-0014">*</xref>
</th>
                      <th align="center" rowspan="2" valign="top" colspan="1">
                        <p>Estimate of Difference</p>
                        <p>(95% CI)<xref ref-type="fn" rid="jah35425-note-0014">*</xref>
<sup>,</sup>
<xref ref-type="fn" rid="jah35425-note-0015"><sup>†</sup></xref>
</p>
                      </th>
                      <th align="center" rowspan="2" valign="top" colspan="1"><italic>P</italic> Value for Interaction<xref ref-type="fn" rid="jah35425-note-0014">*</xref>
</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="center" valign="top" rowspan="1" colspan="1">Mean (SD)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">n</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Mean (SD)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">n</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" colspan="8" rowspan="1">Pre‐specified subgroup analyses</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="8" rowspan="1">Peak VO<sub>2</sub>, mL/min per kg</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">VO<sub>2</sub> ≤16</td>
                      <td align="left" rowspan="1" colspan="1">11.2 (4.4)</td>
                      <td align="left" rowspan="1" colspan="1">60</td>
                      <td align="left" rowspan="1" colspan="1">11.9 (3.7)</td>
                      <td align="left" rowspan="1" colspan="1">63</td>
                      <td align="left" rowspan="1" colspan="1">−0.56 (−1.85 to 0.73)</td>
                      <td align="left" rowspan="1" colspan="1">0.64 (−1.38 to 2.66)</td>
                      <td align="left" rowspan="1" colspan="1">0.54</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">VO<sub>2</sub> &gt;16</td>
                      <td align="left" rowspan="1" colspan="1">18.1 (3.9)</td>
                      <td align="left" rowspan="1" colspan="1">43</td>
                      <td align="left" rowspan="1" colspan="1">18.2 (4.6)</td>
                      <td align="left" rowspan="1" colspan="1">43</td>
                      <td align="left" rowspan="1" colspan="1">0.07 (−1.47 to 1.62)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="8" rowspan="1">Age, y</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Age ≤ median<xref ref-type="fn" rid="jah35425-note-0016">‡</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">14.4 (6.3)</td>
                      <td align="left" rowspan="1" colspan="1">54</td>
                      <td align="left" rowspan="1" colspan="1">16.6 (4.8)</td>
                      <td align="left" rowspan="1" colspan="1">53</td>
                      <td align="left" rowspan="1" colspan="1">−1.40 (−2.76 to −0.05)</td>
                      <td align="left" rowspan="1" colspan="1">2.24 (0.28 to 4.20)</td>
                      <td align="left" rowspan="1" colspan="1">0.03</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Age &gt; median</td>
                      <td align="left" rowspan="1" colspan="1">13.7 (4.3)</td>
                      <td align="left" rowspan="1" colspan="1">49</td>
                      <td align="left" rowspan="1" colspan="1">12.3 (4.6)</td>
                      <td align="left" rowspan="1" colspan="1">53</td>
                      <td align="left" rowspan="1" colspan="1">0.83 (−0.55 to 2.22)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="8" rowspan="1">BMI, kg/m<sup>2</sup>
</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">BMI &lt;25</td>
                      <td align="left" rowspan="1" colspan="1">14.7 (3.9)</td>
                      <td align="left" rowspan="1" colspan="1">14</td>
                      <td align="left" rowspan="1" colspan="1">15.2 (4.9)</td>
                      <td align="left" rowspan="1" colspan="1">14</td>
                      <td align="left" rowspan="1" colspan="1">0.30 (−2.40 to 2.99)</td>
                      <td align="left" rowspan="1" colspan="1">…</td>
                      <td align="left" rowspan="1" colspan="1">0.13</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">25 to &lt;30</td>
                      <td align="left" rowspan="1" colspan="1">14.9 (6.5)</td>
                      <td align="left" rowspan="1" colspan="1">43</td>
                      <td align="left" rowspan="1" colspan="1">16.4 (5.0)</td>
                      <td align="left" rowspan="1" colspan="1">36</td>
                      <td align="left" rowspan="1" colspan="1">−1.59 (−3.21 to 0.02)</td>
                      <td align="left" rowspan="1" colspan="1">−1.89 (−5.05 to 1.27)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">BMI ≥30</td>
                      <td align="left" rowspan="1" colspan="1">13.0 (4.5)</td>
                      <td align="left" rowspan="1" colspan="1">46</td>
                      <td align="left" rowspan="1" colspan="1">13.0 (5.0)</td>
                      <td align="left" rowspan="1" colspan="1">55</td>
                      <td align="left" rowspan="1" colspan="1">0.58 (−0.85 to 2.00)</td>
                      <td align="left" rowspan="1" colspan="1">0.28 (−2.79 to 3.35)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="8" rowspan="1">Sex</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Women</td>
                      <td align="left" rowspan="1" colspan="1">11.0 (3.7)</td>
                      <td align="left" rowspan="1" colspan="1">20</td>
                      <td align="left" rowspan="1" colspan="1">12.1 (2.9)</td>
                      <td align="left" rowspan="1" colspan="1">26</td>
                      <td align="left" rowspan="1" colspan="1">−0.41 (−2.54 to 1.72)</td>
                      <td align="left" rowspan="1" colspan="1">0.14 (−2.28 to 2.57)</td>
                      <td align="left" rowspan="1" colspan="1">0.91</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Men</td>
                      <td align="left" rowspan="1" colspan="1">14.8 (5.5)</td>
                      <td align="left" rowspan="1" colspan="1">83</td>
                      <td align="left" rowspan="1" colspan="1">15.2 (5.5)</td>
                      <td align="left" rowspan="1" colspan="1">80</td>
                      <td align="left" rowspan="1" colspan="1">−0.27 (−1.39 to 0.86)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="8" rowspan="1">Systolic blood pressure, mm Hg</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">SBP ≤ median<xref ref-type="fn" rid="jah35425-note-0016">‡</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">13.5 (6.2)</td>
                      <td align="left" rowspan="1" colspan="1">52</td>
                      <td align="left" rowspan="1" colspan="1">14.8 (5.2)</td>
                      <td align="left" rowspan="1" colspan="1">54</td>
                      <td align="left" rowspan="1" colspan="1">−0.71 (−2.10 to 0.68)</td>
                      <td align="left" rowspan="1" colspan="1">0.93 (−1.06 to 2.93)</td>
                      <td align="left" rowspan="1" colspan="1">0.36</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">SBP &gt; median</td>
                      <td align="left" rowspan="1" colspan="1">14.6 (4.4)</td>
                      <td align="left" rowspan="1" colspan="1">51</td>
                      <td align="left" rowspan="1" colspan="1">14.0 (5.1)</td>
                      <td align="left" rowspan="1" colspan="1">51</td>
                      <td align="left" rowspan="1" colspan="1">0.23 (−1.19 to 1.64)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="8" rowspan="1">Diastolic blood pressure, mm Hg</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">DBP ≤ median<xref ref-type="fn" rid="jah35425-note-0016">‡</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">13.5 (5.6)</td>
                      <td align="left" rowspan="1" colspan="1">54</td>
                      <td align="left" rowspan="1" colspan="1">13.7 (5.2)</td>
                      <td align="left" rowspan="1" colspan="1">58</td>
                      <td align="left" rowspan="1" colspan="1">−0.24 (−1.58 to 1.11)</td>
                      <td align="left" rowspan="1" colspan="1">−0.09 (−2.08 to 1.90)</td>
                      <td align="left" rowspan="1" colspan="1">0.93</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">DBP &gt; median</td>
                      <td align="left" rowspan="1" colspan="1">14.7 (5.1)</td>
                      <td align="left" rowspan="1" colspan="1">49</td>
                      <td align="left" rowspan="1" colspan="1">15.3 (5.0)</td>
                      <td align="left" rowspan="1" colspan="1">47</td>
                      <td align="left" rowspan="1" colspan="1">−0.33 (−1.78 to 1.12)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" colspan="8" rowspan="1">Post‐hoc subgroup analysis</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" colspan="8" rowspan="1">E/E’</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">E/E’ &lt;10</td>
                      <td align="left" rowspan="1" colspan="1">15.3 (5.2)</td>
                      <td align="left" rowspan="1" colspan="1">56</td>
                      <td align="left" rowspan="1" colspan="1">15.1 (5.1)</td>
                      <td align="left" rowspan="1" colspan="1">58</td>
                      <td align="left" rowspan="1" colspan="1">−0.26 (−1.60 to 1.10)</td>
                      <td align="left" rowspan="1" colspan="1">…</td>
                      <td align="left" rowspan="1" colspan="1">0.73</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">10 &lt;14</td>
                      <td align="left" rowspan="1" colspan="1">13.0 (4.9)</td>
                      <td align="left" rowspan="1" colspan="1">34</td>
                      <td align="left" rowspan="1" colspan="1">13.9 (5.5)</td>
                      <td align="left" rowspan="1" colspan="1">30</td>
                      <td align="left" rowspan="1" colspan="1">0.06 (−1.75 to 1.85)</td>
                      <td align="left" rowspan="1" colspan="1">0.31 (−1.95 to 2.58)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:15%" rowspan="1" colspan="1">E/E’ ≥14</td>
                      <td align="left" rowspan="1" colspan="1">11.2 (6.2)</td>
                      <td align="left" rowspan="1" colspan="1">13</td>
                      <td align="left" rowspan="1" colspan="1">13.4 (4.8)</td>
                      <td align="left" rowspan="1" colspan="1">18</td>
                      <td align="left" rowspan="1" colspan="1">−1.23 (−3.86 to 1.40)</td>
                      <td align="left" rowspan="1" colspan="1">−0.97 (−3.93 to 1.99)</td>
                      <td align="left" rowspan="1" colspan="1"/>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah35425-ntgp-0004">
                  <fn id="jah35425-note-0013">
                    <p>BMI indicates body mass index; DBP, diastolic blood pressure; and SBP, systolic blood pressure; and VO<sub>2peak,</sub> peak oxygen consumption; mean is unadjusted.</p>
                  </fn>
                  <fn id="jah35425-note-0014">
                    <label>a</label>
                    <p>The mean differences between the spironolactone group and the placebo group, 95% CIs, and the corresponding <italic>P</italic> values were estimated from linear regression models adjusting for the baseline continuous peak oxygen consumption score.</p>
                  </fn>
                  <fn id="jah35425-note-0015">
                    <label>b</label>
                    <p>The lower level was always treated as the reference group for the estimates of treatment difference apart from sex for which women were the reference group.</p>
                  </fn>
                  <fn id="jah35425-note-0016">
                    <label>c</label>
                    <p>The median age is 72.58 years, median systolic blood pressure is 129 mm Hg, and median diastolic blood pressure is 74 mm Hg (placebo group is the reference group).</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>There was no difference between random groups in any of the secondary outcomes (Table <xref rid="jah35425-tbl-0002" ref-type="table">2</xref>, Table <xref rid="jah35425-sup-0001" ref-type="supplementary-material">S4</xref>). The findings remained consistent after adjustment of age, sex, and body mass index for all outcomes (Tables <xref rid="jah35425-sup-0001" ref-type="supplementary-material">S3 and S4</xref>). Spontaneous return to sinus rhythm on ECG performed at 2 years was uncommon in both study groups (4 [4%] in placebo group and 8 [8%] in spironolactone group, <italic>P</italic>=0.21) (Table <xref rid="jah35425-tbl-0004" ref-type="table">4</xref>, Table <xref rid="jah35425-sup-0001" ref-type="supplementary-material">S5</xref>). At least 1 hospitalization was observed in 15% of patients in spironolactone group and 23% in placebo group (hazard ratio, 0.65; 95% CI, 0.36–1.17) (Table <xref rid="jah35425-tbl-0004" ref-type="table">4</xref>, Figure <xref rid="jah35425-fig-0002" ref-type="fig">2</xref>, Table <xref rid="jah35425-sup-0001" ref-type="supplementary-material">S5</xref>). There was no significant difference in overall mortality, death from cardiac causes, hospitalizations because of cardiac causes, and rates of stroke and systemic thromboembolism between the study arms (Tables <xref rid="jah35425-sup-0001" ref-type="supplementary-material">S6 through S8</xref>). Patients in the spironolactone group had a higher occurrence of breast pain (17 versus 5 in controls), breast swelling (11 versus 4 in controls), and hyperkalaemia (≥5.1 mmol/L, 46 versus 17 in controls) (Table <xref rid="jah35425-sup-0001" ref-type="supplementary-material">S6</xref>).</p>
              <table-wrap id="jah35425-tbl-0004" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                <label>Table 4</label>
                <caption>
                  <p>Secondary Outcomes: Return to Sinus Rhythm and Hospitalization for All Causes</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <thead valign="top">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="top" rowspan="1" colspan="1">Analyses at 2 y</th>
                      <th align="center" colspan="2" valign="top" rowspan="1">Spironolactone</th>
                      <th align="center" colspan="2" valign="top" rowspan="1">Placebo</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Odds Ratio (95% CI)</th>
                      <th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Sinus rhythm, n (%)<xref ref-type="fn" rid="jah35425-note-0017">*</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">n=101</td>
                      <td align="left" rowspan="1" colspan="1">8 (8%)</td>
                      <td align="left" rowspan="1" colspan="1">n=106</td>
                      <td align="left" rowspan="1" colspan="1">4 (4%)</td>
                      <td align="left" rowspan="1" colspan="1">2.19 (0.64–7.52)<xref ref-type="fn" rid="jah35425-note-0018">†</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">0.21<xref ref-type="fn" rid="jah35425-note-0018">†</xref>
</td>
                    </tr>
                    <tr>
                      <td align="left" colspan="7" rowspan="1">Hospitalization for all causes</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Participants with at least 1 event, n (%)</td>
                      <td align="left" rowspan="1" colspan="1">n=118</td>
                      <td align="left" rowspan="1" colspan="1">18 (15%)<xref ref-type="fn" rid="jah35425-note-0019">‡</xref>
</td>
                      <td align="left" rowspan="1" colspan="1">n=123</td>
                      <td align="left" rowspan="1" colspan="1">28 (23%)</td>
                      <td align="left" rowspan="2" colspan="1">0.65 (0.36–1.17)<xref ref-type="fn" rid="jah35425-note-0020">§</xref>
</td>
                      <td align="left" rowspan="2" colspan="1">0.15<xref ref-type="fn" rid="jah35425-note-0020">§</xref>
</td>
                    </tr>
                    <tr>
                      <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Incidence rate (no. per 10 000 person‐days)</td>
                      <td align="left" rowspan="1" colspan="1">n=118</td>
                      <td align="left" rowspan="1" colspan="1">2.46</td>
                      <td align="left" rowspan="1" colspan="1">n=123</td>
                      <td align="left" rowspan="1" colspan="1">3.78</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah35425-ntgp-0005">
                  <fn id="jah35425-note-0017">
                    <label>a</label>
                    <p>Spontaneous return to sinus rhythm on ECG.</p>
                  </fn>
                  <fn id="jah35425-note-0018">
                    <label>b</label>
                    <p>The odds ratios, 95% CIs, and the corresponding <italic>P</italic> values were estimated from a logistic regression model, after adjustment for the continuous baseline peak oxygen consumption.</p>
                  </fn>
                  <fn id="jah35425-note-0019">
                    <label>c</label>
                    <p>One first hospitalized event had no date and was excluded from the time‐to‐event analysis.</p>
                  </fn>
                  <fn id="jah35425-note-0020">
                    <label>d</label>
                    <p>The adjusted hazard ratio, 95% CIs, and the corresponding <italic>P</italic> values were estimated from a Cox regression model adjusting for the baseline continuous peak oxygen consumption score for the primary analysis (placebo group is the reference group).</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <fig fig-type="Figure" xml:lang="en" id="jah35425-fig-0002" orientation="portrait" position="float">
                <label>Figure 2</label>
                <caption>
                  <title>Kaplan–Meier plot of time to first hospitalization.</title>
                  <p> </p>
                </caption>
                <graphic id="nlm-graphic-3" xlink:href="JAH3-9-e016239-g002"/>
              </fig>
            </sec>
            <sec sec-type="discussion" id="jah35425-sec-0014">
              <title>Discussion</title>
              <p>Mechanistic studies have demonstrated that elevation in cardiac filling pressures (estimated by E/e' in this trial) contributes to pulmonary limitations and impaired VO<sub>2peak</sub>.<xref rid="jah35425-bib-0024" ref-type="ref"><sup>24</sup></xref>, <xref rid="jah35425-bib-0025" ref-type="ref"><sup>25</sup></xref> Treatment with spironolactone in the IMPRESS‐AF study does not improve either exercise capacity or quality of life in this cohort of stable patients with permanent AF with preserved ejection fraction despite lowering BP. CIs excluded clinically important effects. On the contrary, kidney function, assessed by estimated glomerular filtration rate, worsened in patients randomized to spironolactone.</p>
              <p>Clinical trials of the aldosterone antagonists spironolactone and eplerenone (RALES, EPHESUS [Eplerenone Post‐AMI Heart Failure Efficacy and Survival Study], EMPHASIS‐HF [Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study]) uniformly showed their clinical benefits in systolic heart failure. The IMPRESS‐AF study conclusively demonstrates that use of an aldosterone antagonist, spironolactone does not improve aerobic capacity, estimated filling pressures, or quality of life in patients with AF without systolic impairment, and generally consistent with the overall lack of effect in patients with heart failure and preserved ejection fraction found in the ALDO‐DHF (Aldosterone Receptor Blockade in Diastolic Heart Failure)<xref rid="jah35425-bib-0026" ref-type="ref"><sup>26</sup></xref> and TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist)<xref rid="jah35425-bib-0027" ref-type="ref"><sup>27</sup></xref> trials. Of interest, in the ALDO‐DHF trial of predominantly hypertension‐related heart failure and preserved ejection fraction aldosterone inhibition reduced E/e' but did not increase in VO<sub>2peak</sub>, and in another trial spironolactone improved VO<sub>2peak</sub> and reduced exercise‐induced increase in E/e' in a selected population of patients with heart failure and preserved ejection fraction that excluded patients with AF.<xref rid="jah35425-bib-0026" ref-type="ref"><sup>26</sup></xref>, <xref rid="jah35425-bib-0028" ref-type="ref"><sup>28</sup></xref> Of note, although the TOPCAT trial showed overall neutral results this may be confounded by the quality issues in Eastern Europe.<xref rid="jah35425-bib-0029" ref-type="ref"><sup>29</sup></xref> In the IMPRESS‐AF trial, the hospitalization rates were numerically higher in the placebo arm. A larger study that is powered for hospitalizations and cardiovascular death might produce other results, although such a study would be difficult to justify based on the overall results of spironolactone trials in patients with preserved ejection fraction.</p>
              <p>Although patients receiving spironolactone had numerically more cases of spontaneous return to sinus rhythm such cases were few in both study arms, the difference was not significant statistically, and could therefore be a chance finding. The recently published RACE‐3 trial suggested that a complex intervention including spironolactone was associated with a higher rate of sinus rhythm maintenance at 1 year (<italic>P</italic>=0.042).<xref rid="jah35425-bib-0011" ref-type="ref"><sup>11</sup></xref> The RACE‐3 intervention consisted of mineralocorticoid receptor antagonists, statins, angiotensin‐converting enzyme inhibitors and/or angiotensin receptor blockers, and cardiac rehabilitation.<xref rid="jah35425-bib-0011" ref-type="ref"><sup>11</sup></xref> Among the targeted trial medicines, the mineralocorticoid receptor antagonists showed the most prominent contrast in use (85% in the treatment group and 4% in the control group). Whilst the RACE‐3 trial indicated the mineralocorticoid receptor antagonists could help maintenance of the sinus rhythm in the recent onset AF, spontaneous return in sinus rhythm was infrequent in both arms of the IMPRESS‐AF trial. The actual baseline VO<sub>2peak</sub> of 14.25 mL/kg per minute was lower than the projected 16 mL/kg per minute, possibly reflecting the background chronic AF, but this is unlikely to affect the study conclusions.</p>
              <p>Overall, spironolactone was well tolerated. There were comparable rates of withdrawal from the study in the treatment and control groups. As expected, spironolactone reduced BP, thus demonstrating adequate overall compliance with the drug as confirmed by the expected effect. However, we found a safety signal as there was a reduction of 6.0 mL/kg in the estimated glomerular filtration rate over 2 years. These data indicate potential harm to the kidney caused by treating patients with AF with spironolactone. However, most patients with pharmacological inhibition of renin‐angiotensin‐aldosterone system, including spironolactone have hemodynamically mediated reductions in glomerular filtration rates.<xref rid="jah35425-bib-0030" ref-type="ref"><sup>30</sup></xref> These changes can be renal protective by decreasing chronic glomerular hyperfiltration in patients with chronic kidney disease and they may have contributed the decrease in HF hospitalization that was observed in the TOPCAT trial. Not unexpectedly, a higher occurrence of breast pain/swelling and hyperkalemia was noted in the spironolactone group.</p>
              <sec id="jah35425-sec-0015">
                <title>Limitations</title>
                <p>The study outcomes were assessed by tests of physical capacity, but these tests could be inherently affected by various musculoskeletal problems despite every effort to perform the tests until the limits of the cardiac reserve are reached. Although recognized questionnaires were used to assess quality of life, specific validation of the tests in the study population has not been done.</p>
                <p>There was a relatively high drop‐out rate in this study, and overall 16% of patients did not complete the primary outcome tests. However, the study power was estimated to allow 20% loss of the patients during follow‐up, and the validity of the findings was maintained. The study did not have power to reliably define effects of spironolactone on hard outcomes, such as hospitalizations or return to sinus rhythm. However, given the detrimental effects of the drug on kidney function in this trial population further testing of spironolactone will need careful consideration.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="jah35425-sec-0016">
              <title>Conclusions</title>
              <p>Treatment with the aldosterone antagonist, spironolactone in patients with permanent AF and preserved ejection fraction does not improve exercise tolerance, quality of life, and diastolic function. Furthermore, spironolactone leads to worsening of renal function which should be considered in this patient population and use of mineralocorticoid receptor antagonists may mandate closer monitoring of renal function.</p>
            </sec>
            <sec id="jah35425-sec-0018">
              <title>Sources of Funding</title>
              <p>The trial was funded by the NIHR, NIHR‐EME Programme (grant number 12/10/19) with support from NIHR Clinical Research Network West Midlands, United Kingdom. The University of Birmingham was the sponsor of this trial.</p>
            </sec>
            <sec sec-type="COI-statement" id="jah35425-sec-0019">
              <title>Disclosures</title>
              <p>Prof Lip reports acting as a Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi‐Sankyo; Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi‐Sankyo. No fees were directly received personally. Prof Calvert reports grants from NIHR HTA, during the conduct of the study; grants from NIHR Birmingham Biomedical Research Centre, grants from NIHR Surgical Reconstruction and Microbiology Research Centre, grants from Health Data Research UK, grants from Innovate UK, grants from Macmillan Cancer Support, personal fees from PCORI, from Astellas, from Takeda, from Glaukos, from Merck, outside the submitted work. Prof Fisher reports grants from NIHR, during the conduct of the study; grants from BMS/Pfizer, outside the submitted work. Prof Kirchhof is a board member of the European Society of Cardiology and has received travel support from the European Society of Cardiology, including for meetings pertinent to this work, during the conduct of the study; Prof Kirchhof has received research support from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Heart Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies, outside the submitted work; In addition, Prof Kirchhof is listed as an inventor on 2 patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783), pending. The remaining authors have no disclosures to report.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="jah35425-sup-0001">
                <caption>
                  <p>
                    <bold>Data S1</bold>
                  </p>
                  <p>
                    <bold>Tables S1–S8</bold>
                  </p>
                  <p><bold>References</bold><xref rid="jah35425-bib-0031" ref-type="ref"><bold>31</bold></xref>, <xref rid="jah35425-bib-0032" ref-type="ref"><bold>32</bold></xref></p>
                </caption>
                <media xlink:href="JAH3-9-e016239-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jah35425-sec-0017">
              <title>Acknowledgments</title>
              <p>Author contributions: Dr Shantsila wrote the first draft of the report. Dr Sun and Prof Deeks performed statistical analysis and edited the article. Dr Shahid, Prof Gill, Prof Fisher, Prof Kirchhof, and Prof Lip edited the article.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah35425-bibl-0001">
              <title>References</title>
              <ref id="jah35425-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0001"><string-name><surname>Santhanakrishnan</surname><given-names>R</given-names></string-name>, <string-name><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name><surname>Larson</surname><given-names>MG</given-names></string-name>, <string-name><surname>Magnani</surname><given-names>JW</given-names></string-name>, <string-name><surname>McManus</surname><given-names>DD</given-names></string-name>, <string-name><surname>Lubitz</surname><given-names>SA</given-names></string-name>, <string-name><surname>Ellinor</surname><given-names>PT</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Vasan</surname><given-names>RS</given-names></string-name>, <string-name><surname>Lee</surname><given-names>DS</given-names></string-name>, et al. <article-title>Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction</article-title>. <source xml:lang="en">Circulation</source>. <year>2016</year>;<fpage>484</fpage>–<lpage>492</lpage>.<pub-id pub-id-type="pmid">26746177</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0002"><string-name><surname>Corley</surname><given-names>SD</given-names></string-name>, <string-name><surname>Epstein</surname><given-names>AE</given-names></string-name>, <string-name><surname>DiMarco</surname><given-names>JP</given-names></string-name>, <string-name><surname>Domanski</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Geller</surname><given-names>N</given-names></string-name>, <string-name><surname>Greene</surname><given-names>HL</given-names></string-name>, <string-name><surname>Josephson</surname><given-names>RA</given-names></string-name>, <string-name><surname>Kellen</surname><given-names>JC</given-names></string-name>, <string-name><surname>Klein</surname><given-names>RC</given-names></string-name>, <string-name><surname>Krahn</surname><given-names>AD</given-names></string-name>, et al. <article-title>Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow‐Up Investigation of Rhythm Management (AFFIRM) Study</article-title>. <source xml:lang="en">Circulation</source>. <year>2004</year>;<fpage>1509</fpage>–<lpage>1513</lpage>.<pub-id pub-id-type="pmid">15007003</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0003"><string-name><surname>Dzeshka</surname><given-names>MS</given-names></string-name>, <string-name><surname>Lip</surname><given-names>GY</given-names></string-name>, <string-name><surname>Snezhitskiy</surname><given-names>V</given-names></string-name>, <string-name><surname>Shantsila</surname><given-names>E</given-names></string-name>. <article-title>Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2015</year>;<fpage>943</fpage>–<lpage>959</lpage>.<pub-id pub-id-type="pmid">26293766</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0004"><string-name><surname>Normand</surname><given-names>C</given-names></string-name>, <string-name><surname>Kaye</surname><given-names>DM</given-names></string-name>, <string-name><surname>Povsic</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Dickstein</surname><given-names>K</given-names></string-name>. <article-title>Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology</article-title>. <source xml:lang="en">Lancet</source>. <year>2019</year>;<fpage>1045</fpage>–<lpage>1055</lpage>.<pub-id pub-id-type="pmid">30860030</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0005"><string-name><surname>Chua</surname><given-names>W</given-names></string-name>, <string-name><surname>Purmah</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cardoso</surname><given-names>VR</given-names></string-name>, <string-name><surname>Gkoutos</surname><given-names>GV</given-names></string-name>, <string-name><surname>Tull</surname><given-names>SP</given-names></string-name>, <string-name><surname>Neculau</surname><given-names>G</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>MR</given-names></string-name>, <string-name><surname>Kotecha</surname><given-names>D</given-names></string-name>, <string-name><surname>Lip</surname><given-names>GYH</given-names></string-name>, <string-name><surname>Kirchhof</surname><given-names>P</given-names></string-name>, et al. <article-title>Data‐driven discovery and validation of circulating blood‐based biomarkers associated with prevalent atrial fibrillation</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2019</year>;<fpage>1268</fpage>–<lpage>1276</lpage>.<pub-id pub-id-type="pmid">30615112</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0006"><string-name><surname>Weber</surname><given-names>KT</given-names></string-name>. <article-title>Aldosterone in congestive heart failure</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2001</year>;<fpage>1689</fpage>–<lpage>1697</lpage>.<pub-id pub-id-type="pmid">11759649</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0007"><string-name><surname>Burniston</surname><given-names>JG</given-names></string-name>, <string-name><surname>Saini</surname><given-names>A</given-names></string-name>, <string-name><surname>Tan</surname><given-names>LB</given-names></string-name>, <string-name><surname>Goldspink</surname><given-names>DF</given-names></string-name>. <article-title>Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo</article-title>. <source xml:lang="en">J Mol Cell Cardiol</source>. <year>2005</year>;<fpage>395</fpage>–<lpage>399</lpage>.<pub-id pub-id-type="pmid">15907929</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0008"><string-name><surname>Brilla</surname><given-names>CG</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>G</given-names></string-name>, <string-name><surname>Matsubara</surname><given-names>L</given-names></string-name>, <string-name><surname>Weber</surname><given-names>KT</given-names></string-name>. <article-title>Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone</article-title>. <source xml:lang="en">J Mol Cell Cardiol</source>. <year>1994</year>;<fpage>809</fpage>–<lpage>820</lpage>.<pub-id pub-id-type="pmid">7966349</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0009"><string-name><surname>Tsai</surname><given-names>CT</given-names></string-name>, <string-name><surname>Chiang</surname><given-names>FT</given-names></string-name>, <string-name><surname>Tseng</surname><given-names>CD</given-names></string-name>, <string-name><surname>Hwang</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Kuo</surname><given-names>KT</given-names></string-name>, <string-name><surname>Wu</surname><given-names>CK</given-names></string-name>, <string-name><surname>Yu</surname><given-names>CC</given-names></string-name>, <string-name><surname>Wang</surname><given-names>YC</given-names></string-name>, <string-name><surname>Lai</surname><given-names>LP</given-names></string-name>, <string-name><surname>Lin</surname><given-names>JL</given-names></string-name>. <article-title>Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2010</year>;<fpage>758</fpage>–<lpage>770</lpage>.<pub-id pub-id-type="pmid">20170814</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0010"><string-name><surname>Zannad</surname><given-names>F</given-names></string-name>, <string-name><surname>Alla</surname><given-names>F</given-names></string-name>, <string-name><surname>Dousset</surname><given-names>B</given-names></string-name>, <string-name><surname>Perez</surname><given-names>A</given-names></string-name>, <string-name><surname>Pitt</surname><given-names>B</given-names></string-name>. <article-title>Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators</article-title>. <source xml:lang="en">Circulation</source>. <year>2000</year>;<fpage>2700</fpage>–<lpage>2706</lpage>.<pub-id pub-id-type="pmid">11094035</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0011"><string-name><surname>Rienstra</surname><given-names>M</given-names></string-name>, <string-name><surname>Hobbelt</surname><given-names>AH</given-names></string-name>, <string-name><surname>Alings</surname><given-names>M</given-names></string-name>, <string-name><surname>Tijssen</surname><given-names>JGP</given-names></string-name>, <string-name><surname>Smit</surname><given-names>MD</given-names></string-name>, <string-name><surname>Brugemann</surname><given-names>J</given-names></string-name>, <string-name><surname>Geelhoed</surname><given-names>B</given-names></string-name>, <string-name><surname>Tieleman</surname><given-names>RG</given-names></string-name>, <string-name><surname>Hillege</surname><given-names>HL</given-names></string-name>, <string-name><surname>Tukkie</surname><given-names>R</given-names></string-name>, et al. <article-title>Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2018</year>;<fpage>2987</fpage>–<lpage>2996</lpage>.<pub-id pub-id-type="pmid">29401239</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0012"><string-name><surname>Calvert</surname><given-names>M</given-names></string-name>, <string-name><surname>Kyte</surname><given-names>D</given-names></string-name>, <string-name><surname>von Hildebrand</surname><given-names>M</given-names></string-name>, <string-name><surname>King</surname><given-names>M</given-names></string-name>, <string-name><surname>Moher</surname><given-names>D</given-names></string-name>. <article-title>Putting patients at the heart of health‐care research</article-title>. <source xml:lang="en">Lancet</source>. <year>2015</year>;<fpage>1073</fpage>–<lpage>1074</lpage>.<pub-id pub-id-type="pmid">25797557</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0013"><string-name><surname>Shantsila</surname><given-names>E</given-names></string-name>, <string-name><surname>Haynes</surname><given-names>R</given-names></string-name>, <string-name><surname>Calvert</surname><given-names>M</given-names></string-name>, <string-name><surname>Fisher</surname><given-names>J</given-names></string-name>, <string-name><surname>Kirchhof</surname><given-names>P</given-names></string-name>, <string-name><surname>Gill</surname><given-names>PS</given-names></string-name>, <string-name><surname>Lip</surname><given-names>GY</given-names></string-name>. <article-title>IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS‐AF randomised controlled trial</article-title>. <source xml:lang="en">BMJ Open</source>. <year>2016</year>;<elocation-id>e012241</elocation-id>.</mixed-citation>
              </ref>
              <ref id="jah35425-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0014"><string-name><surname>Camm</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Lip</surname><given-names>GY</given-names></string-name>, <string-name><surname>De Caterina</surname><given-names>R</given-names></string-name>, <string-name><surname>Savelieva</surname><given-names>I</given-names></string-name>, <string-name><surname>Atar</surname><given-names>D</given-names></string-name>, <string-name><surname>Hohnloser</surname><given-names>SH</given-names></string-name>, <string-name><surname>Hindricks</surname><given-names>G</given-names></string-name>, <string-name><surname>Kirchhof</surname><given-names>P</given-names></string-name>; <collab collab-type="authors">Guidelines ESCCfP</collab>
. <article-title>2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2012</year>;<fpage>2719</fpage>–<lpage>2747</lpage>.<pub-id pub-id-type="pmid">22922413</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0015"><string-name><surname>Kirchhof</surname><given-names>P</given-names></string-name>, <string-name><surname>Benussi</surname><given-names>S</given-names></string-name>, <string-name><surname>Kotecha</surname><given-names>D</given-names></string-name>, <string-name><surname>Ahlsson</surname><given-names>A</given-names></string-name>, <string-name><surname>Atar</surname><given-names>D</given-names></string-name>, <string-name><surname>Casadei</surname><given-names>B</given-names></string-name>, <string-name><surname>Castella</surname><given-names>M</given-names></string-name>, <string-name><surname>Diener</surname><given-names>HC</given-names></string-name>, <string-name><surname>Heidbuchel</surname><given-names>H</given-names></string-name>, <string-name><surname>Hendriks</surname><given-names>J</given-names></string-name>, et al. <article-title>2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2016</year>;<fpage>2893</fpage>–<lpage>2962</lpage>.<pub-id pub-id-type="pmid">27567408</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0016"><string-name><surname>Rector</surname><given-names>TS</given-names></string-name>, <string-name><surname>Kubo</surname><given-names>SH</given-names></string-name>, <string-name><surname>Cohn</surname><given-names>JN</given-names></string-name>. <article-title>Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo</article-title>. <source xml:lang="en">Am J Cardiol</source>. <year>1993</year>;<fpage>1106</fpage>–<lpage>1107</lpage>.<pub-id pub-id-type="pmid">8475878</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0017"><string-name><surname>Rabin</surname><given-names>R</given-names></string-name>, <string-name><surname>de Charro</surname><given-names>F</given-names></string-name>. <article-title>EQ‐5D: a measure of health status from the EuroQol Group</article-title>. <source xml:lang="en">Ann Med</source>. <year>2001</year>;<fpage>337</fpage>–<lpage>343</lpage>.<pub-id pub-id-type="pmid">11491192</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0018"><string-name><surname>Guazzi</surname><given-names>M</given-names></string-name>, <string-name><surname>Arena</surname><given-names>R</given-names></string-name>, <string-name><surname>Halle</surname><given-names>M</given-names></string-name>, <string-name><surname>Piepoli</surname><given-names>MF</given-names></string-name>, <string-name><surname>Myers</surname><given-names>J</given-names></string-name>, <string-name><surname>Lavie</surname><given-names>CJ</given-names></string-name>. <article-title>2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2018</year>;<fpage>1144</fpage>–<lpage>1161</lpage>.<pub-id pub-id-type="pmid">27141094</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0019"><string-name><surname>Scott</surname><given-names>JM</given-names></string-name>, <string-name><surname>Haykowsky</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Eggebeen</surname><given-names>J</given-names></string-name>, <string-name><surname>Morgan</surname><given-names>TM</given-names></string-name>, <string-name><surname>Brubaker</surname><given-names>PH</given-names></string-name>, <string-name><surname>Kitzman</surname><given-names>DW</given-names></string-name>. <article-title>Reliability of peak exercise testing in patients with heart failure with preserved ejection fraction</article-title>. <source xml:lang="en">Am J Cardiol</source>. <year>2012</year>;<fpage>1809</fpage>–<lpage>1813</lpage>.<pub-id pub-id-type="pmid">22981266</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0020"><string-name><surname>Nagueh</surname><given-names>SF</given-names></string-name>, <string-name><surname>Kopelen</surname><given-names>HA</given-names></string-name>, <string-name><surname>Quinones</surname><given-names>MA</given-names></string-name>. <article-title>Assessment of left ventricular filling pressures by Doppler in the presence of atrial fibrillation</article-title>. <source xml:lang="en">Circulation</source>. <year>1996</year>;<fpage>2138</fpage>–<lpage>2145</lpage>.<pub-id pub-id-type="pmid">8901664</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0021"><string-name><surname>Nagueh</surname><given-names>SF</given-names></string-name>, <string-name><surname>Appleton</surname><given-names>CP</given-names></string-name>, <string-name><surname>Gillebert</surname><given-names>TC</given-names></string-name>, <string-name><surname>Marino</surname><given-names>PN</given-names></string-name>, <string-name><surname>Oh</surname><given-names>JK</given-names></string-name>, <string-name><surname>Smiseth</surname><given-names>OA</given-names></string-name>, <string-name><surname>Waggoner</surname><given-names>AD</given-names></string-name>, <string-name><surname>Flachskampf</surname><given-names>FA</given-names></string-name>, <string-name><surname>Pellikka</surname><given-names>PA</given-names></string-name>, <string-name><surname>Evangelisa</surname><given-names>A</given-names></string-name>. <article-title>Recommendations for the evaluation of left ventricular diastolic function by echocardiography</article-title>. <source xml:lang="en">Eur J Echocardiogr</source>. <year>2009</year>;<fpage>165</fpage>–<lpage>193</lpage>.</mixed-citation>
              </ref>
              <ref id="jah35425-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0022"><string-name><surname>Calvert</surname><given-names>M</given-names></string-name>, <string-name><surname>Blazeby</surname><given-names>J</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name><surname>Revicki</surname><given-names>DA</given-names></string-name>, <string-name><surname>Moher</surname><given-names>D</given-names></string-name>, <string-name><surname>Brundage</surname><given-names>MD</given-names></string-name>; <collab collab-type="authors">Group CP</collab>
. <article-title>Reporting of patient‐reported outcomes in randomized trials: the CONSORT PRO extension</article-title>. <source xml:lang="en">JAMA</source>. <year>2013</year>;<fpage>814</fpage>–<lpage>822</lpage>.<pub-id pub-id-type="pmid">23443445</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0023"><string-name><surname>Cicoira</surname><given-names>M</given-names></string-name>, <string-name><surname>Zanolla</surname><given-names>L</given-names></string-name>, <string-name><surname>Rossi</surname><given-names>A</given-names></string-name>, <string-name><surname>Golia</surname><given-names>G</given-names></string-name>, <string-name><surname>Franceschini</surname><given-names>L</given-names></string-name>, <string-name><surname>Brighetti</surname><given-names>G</given-names></string-name>, <string-name><surname>Marino</surname><given-names>P</given-names></string-name>, <string-name><surname>Zardini</surname><given-names>P</given-names></string-name>. <article-title>Long‐term, dose‐dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2002</year>;<fpage>304</fpage>–<lpage>310</lpage>.<pub-id pub-id-type="pmid">12106936</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0024"><string-name><surname>Obokata</surname><given-names>M</given-names></string-name>, <string-name><surname>Olson</surname><given-names>TP</given-names></string-name>, <string-name><surname>Reddy</surname><given-names>YNV</given-names></string-name>, <string-name><surname>Melenovsky</surname><given-names>V</given-names></string-name>, <string-name><surname>Kane</surname><given-names>GC</given-names></string-name>, <string-name><surname>Borlaug</surname><given-names>BA</given-names></string-name>. <article-title>Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2018</year>;<fpage>2810</fpage>–<lpage>2821</lpage>.<pub-id pub-id-type="pmid">29788047</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0025"><string-name><surname>Reddy</surname><given-names>YNV</given-names></string-name>, <string-name><surname>Olson</surname><given-names>TP</given-names></string-name>, <string-name><surname>Obokata</surname><given-names>M</given-names></string-name>, <string-name><surname>Melenovsky</surname><given-names>V</given-names></string-name>, <string-name><surname>Borlaug</surname><given-names>BA</given-names></string-name>. <article-title>Hemodynamic correlates and diagnostic role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction</article-title>. <source xml:lang="en">JACC Heart Fail</source>. <year>2018</year>;<fpage>665</fpage>–<lpage>675</lpage>.<pub-id pub-id-type="pmid">29803552</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0026"><string-name><surname>Edelmann</surname><given-names>F</given-names></string-name>, <string-name><surname>Wachter</surname><given-names>R</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>AG</given-names></string-name>, <string-name><surname>Kraigher‐Krainer</surname><given-names>E</given-names></string-name>, <string-name><surname>Colantonio</surname><given-names>C</given-names></string-name>, <string-name><surname>Kamke</surname><given-names>W</given-names></string-name>, <string-name><surname>Duvinage</surname><given-names>A</given-names></string-name>, <string-name><surname>Stahrenberg</surname><given-names>R</given-names></string-name>, <string-name><surname>Durstewitz</surname><given-names>K</given-names></string-name>, <string-name><surname>Loffler</surname><given-names>M</given-names></string-name>, et al. <article-title>Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo‐DHF randomized controlled trial</article-title>. <source xml:lang="en">JAMA</source>. <year>2013</year>;<fpage>781</fpage>–<lpage>791</lpage>.<pub-id pub-id-type="pmid">23443441</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0027"><string-name><surname>Pitt</surname><given-names>B</given-names></string-name>, <string-name><surname>Pfeffer</surname><given-names>MA</given-names></string-name>, <string-name><surname>Assmann</surname><given-names>SF</given-names></string-name>, <string-name><surname>Boineau</surname><given-names>R</given-names></string-name>, <string-name><surname>Anand</surname><given-names>IS</given-names></string-name>, <string-name><surname>Claggett</surname><given-names>B</given-names></string-name>, <string-name><surname>Clausell</surname><given-names>N</given-names></string-name>, <string-name><surname>Desai</surname><given-names>AS</given-names></string-name>, <string-name><surname>Diaz</surname><given-names>R</given-names></string-name>, <string-name><surname>Fleg</surname><given-names>JL</given-names></string-name>, et al. <article-title>Spironolactone for heart failure with preserved ejection fraction</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2014</year>;<fpage>1383</fpage>–<lpage>1392</lpage>.<pub-id pub-id-type="pmid">24716680</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0028"><string-name><surname>Kosmala</surname><given-names>W</given-names></string-name>, <string-name><surname>Rojek</surname><given-names>A</given-names></string-name>, <string-name><surname>Przewlocka‐Kosmala</surname><given-names>M</given-names></string-name>, <string-name><surname>Wright</surname><given-names>L</given-names></string-name>, <string-name><surname>Mysiak</surname><given-names>A</given-names></string-name>, <string-name><surname>Marwick</surname><given-names>TH</given-names></string-name>. <article-title>Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2016</year>;<fpage>1823</fpage>–<lpage>1834</lpage>.<pub-id pub-id-type="pmid">27765184</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0029"><string-name><surname>Pfeffer</surname><given-names>MA</given-names></string-name>, <string-name><surname>Claggett</surname><given-names>B</given-names></string-name>, <string-name><surname>Assmann</surname><given-names>SF</given-names></string-name>, <string-name><surname>Boineau</surname><given-names>R</given-names></string-name>, <string-name><surname>Anand</surname><given-names>IS</given-names></string-name>, <string-name><surname>Clausell</surname><given-names>N</given-names></string-name>, <string-name><surname>Desai</surname><given-names>AS</given-names></string-name>, <string-name><surname>Diaz</surname><given-names>R</given-names></string-name>, <string-name><surname>Fleg</surname><given-names>JL</given-names></string-name>, <string-name><surname>Gordeev</surname><given-names>I</given-names></string-name>, et al. <article-title>Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial</article-title>. <source xml:lang="en">Circulation</source>. <year>2015</year>;<fpage>34</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">25406305</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0030"><string-name><surname>Bianchi</surname><given-names>S</given-names></string-name>, <string-name><surname>Bigazzi</surname><given-names>R</given-names></string-name>, <string-name><surname>Campese</surname><given-names>VM</given-names></string-name>. <article-title>Long‐term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease</article-title>. <source xml:lang="en">Kidney Int</source>. <year>2006</year>;<fpage>2116</fpage>–<lpage>2123</lpage>.</mixed-citation>
              </ref>
              <ref id="jah35425-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0031"><string-name><surname>Little</surname><given-names>RJA</given-names></string-name>. <article-title>Missing‐data adjustments in large surveys</article-title>. <source xml:lang="en">J Bus Econ Stat</source>. <year>1988</year>;<fpage>287</fpage>–<lpage>296</lpage>.</mixed-citation>
              </ref>
              <ref id="jah35425-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="book" id="jah35425-cit-0032"><string-name><surname>Rubin</surname><given-names>DB</given-names></string-name>. <source xml:lang="en">Multiple Imputation for Nonresponse in Surveys</source>. <publisher-loc>New York, Chichester, Brisbane, Toronto, Singapore</publisher-loc>: <publisher-name>Wiley</publisher-name>; <year>1987</year>.</mixed-citation>
              </ref>
              <ref id="jah35425-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0033"><string-name><surname>Shafiq</surname><given-names>A</given-names></string-name>, <string-name><surname>Brawner</surname><given-names>CA</given-names></string-name>, <string-name><surname>Aldred</surname><given-names>HA</given-names></string-name>, <string-name><surname>Lewis</surname><given-names>B</given-names></string-name>, <string-name><surname>Williams</surname><given-names>CT</given-names></string-name>, <string-name><surname>Tita</surname><given-names>C</given-names></string-name>, <string-name><surname>Schairer</surname><given-names>JR</given-names></string-name>, <string-name><surname>Ehrman</surname><given-names>JK</given-names></string-name>, <string-name><surname>Velez</surname><given-names>M</given-names></string-name>, <string-name><surname>Selektor</surname><given-names>Y</given-names></string-name>, et al. <article-title>Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry Ford HospITal CardioPulmonary EXercise Testing (FIT‐CPX) project</article-title>. <source xml:lang="en">Am Heart J</source>. <year>2016</year>;<fpage>167</fpage>–<lpage>172</lpage>.<pub-id pub-id-type="pmid">26995385</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0034"><string-name><surname>Swank</surname><given-names>AM</given-names></string-name>, <string-name><surname>Horton</surname><given-names>J</given-names></string-name>, <string-name><surname>Fleg</surname><given-names>JL</given-names></string-name>, <string-name><surname>Fonarow</surname><given-names>GC</given-names></string-name>, <string-name><surname>Keteyian</surname><given-names>S</given-names></string-name>, <string-name><surname>Goldberg</surname><given-names>L</given-names></string-name>, <string-name><surname>Wolfel</surname><given-names>G</given-names></string-name>, <string-name><surname>Handberg</surname><given-names>EM</given-names></string-name>, <string-name><surname>Bensimhon</surname><given-names>D</given-names></string-name>, <string-name><surname>Illiou</surname><given-names>MC</given-names></string-name>, et al. <article-title>Modest increase in peak VO<sub>2</sub> is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training</article-title>. <source xml:lang="en">Circ Heart Fail</source>. <year>2012</year>;<fpage>579</fpage>–<lpage>585</lpage>.<pub-id pub-id-type="pmid">22773109</pub-id></mixed-citation>
              </ref>
              <ref id="jah35425-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah35425-cit-0035"><string-name><surname>Edelmann</surname><given-names>F</given-names></string-name>, <string-name><surname>Gelbrich</surname><given-names>G</given-names></string-name>, <string-name><surname>Dungen</surname><given-names>HD</given-names></string-name>, <string-name><surname>Frohling</surname><given-names>S</given-names></string-name>, <string-name><surname>Wachter</surname><given-names>R</given-names></string-name>, <string-name><surname>Stahrenberg</surname><given-names>R</given-names></string-name>, <string-name><surname>Binder</surname><given-names>L</given-names></string-name>, <string-name><surname>Topper</surname><given-names>A</given-names></string-name>, <string-name><surname>Lashki</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Schwarz</surname><given-names>S</given-names></string-name>, et al. <article-title>Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex‐DHF (Exercise training in Diastolic Heart Failure) pilot study</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2011</year>;<fpage>1780</fpage>–<lpage>1791</lpage>.<pub-id pub-id-type="pmid">21996391</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
